Results 11 to 20 of about 1,254,012 (356)
Objective: Meta analysis was used to explore the efficacy and safety of Sintilimab in the treatment of cancer.Methods: The databases of CNKI, VIP, Wanfang Data, PubMed, ScienceDirect, the Cochrane Library and EMBASE were searched by computer to collect ...
Ziqi Ye +6 more
doaj +1 more source
Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma [PDF]
BACKGROUND: Meningiomas are the most common primary tumors of the central nervous system. In patients with WHO grade I meningiomas no adjuvant therapy is recommended after resection.
Acker, Güliz +9 more
core +1 more source
Conversion of a gastric band into an intraperitoneal port in a patient with optimally debulked stage 3C serous ovarian carcinoma [PDF]
Intraperitoneal (IP) chemotherapy in women with optimally debulked stage 3 ovarian cancer improves overall survival and progression-free survival, and its use has been encouraged in the adjuvant treatment of appropriately selected patients (Armstrong et ...
Cohen, P, Tan, J, Tan, J, Tucker, P
core +2 more sources
Introduction Talaromyces marneffei (T. marneffei), a dimorphic fungus, causes local or disseminated infection in humans. We aimed to analyze the clinical characteristics, prognostic factors, and survival outcomes of patients with T.
QingLiang Yu +14 more
doaj +1 more source
Detecting Overall Survival Benefit Derived From Survival Postprogression Rather Than Progression-Free Survival [PDF]
Broglio and Berry (2009) examined the impact of survival postprogression (SPP) on overall survival (OS) when progression-free survival (PFS) was used to assess treatment effect in metastatic cancer. Their simulation studies found no statistical difference in OS because of dilution effect from SPP, although there was a statistical difference in PFS ...
Morita, S, Sakamaki, K, Yin, G
openaire +4 more sources
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England [PDF]
Background: Nivolumab was the first programmed death receptor 1 (PD-1) immune checkpoint inhibitor to demonstrate long-term survival benefit in a clinical trial setting for advanced melanoma patients.
Ellis, John +8 more
core +1 more source
Neutropenia is the most frequent dose-limiting toxicity reported in patients with metastatic breast cancer receiving palbociclib. The objective of this study was to investigate the pharmacokinetic–pharmacodynamic (PK/PD) relationships for toxicity (i.e.,
Perrine Courlet +15 more
doaj +1 more source
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients [PDF]
Objective: Topoisomerase 1 (topo-1) is an important target for the treatment of metastatic colorectal cancer (CRC). The aim of the present study was to evaluate the correlation between topo-1 single-nucleotide polymorphisms (SNPs) and clinical outcome in
Crea, F. +11 more
core +1 more source
Prognostic factors and survival study in high-grade glioma in a hospital in Lima, Peru
Introduction: Gliomas are primary tumors of the central nervous system. They are classifiedfrom grade I-IV, with high grade III and IV being the most frequent and with poor prognosis. Objective: To determine the prognostic factors of survival in patients
Paul Méndez-Aguilar +1 more
doaj +1 more source
Outcome of Primary CNS Lymphoma; A Retrospective Analysis
Background: Rituximab along with high dose Methotrexate is nowadays the standard of care in treatment of PCNSL. We report the retrospective analysis of PCNSL patients who were treated with and without Rituximab at Aga Khan University Hospital, Karachi ...
Mehwish Shahzadi +3 more
doaj +1 more source

